Bilateral Vitreous Hemorrhage Following Bilateral Intravitreal Injections of Bevacizumab in an Infant With Retinopathy of Prematurity.
Since the publication of BEAT-ROP in 2011, intravitreal bevacizumab (IVB) has become increasingly common for the treatment of posterior type 1 retinopathy of prematurity (ROP). However, long-term data on the safety and efficacy of IVB for ROP are lacking. Vitreous hemorrhage following bevacizumab injections have been rarely reported in infants with ROP, and the need for treatment of these hemorrhages remains in question. Here, the authors report a case of bilateral vitreous hemorrhage in a premature infant within 2 weeks of bilateral intravitreal injections of bevacizumab. These hemorrhages resolved without intervention with regression of ROP in both eyes. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:893-896.].